gpi13 Antibody

What is GPI13 and what is its role in glycosylphosphatidylinositol biosynthesis?

GPI13 (in yeast) or PIGO (its mammalian homolog) functions as a critical component of the GPI-ethanolamine phosphate transferase-III complex alongside PIGF (mammalian) or Gpi11 (yeast). This enzyme complex is responsible for adding ethanolamine phosphate (EtNP) to the third mannose residue of the GPI anchor during biosynthesis .

The GPI biosynthetic pathway involves over 20 intramembrane catalytic steps, with the final structure typically characterized by a complex glycan core of α-Man3-(1→2)-α-Man2-(1→6)-α-Man1-(1→4)-α-GlcN . Interestingly, while yeast SMP3 (homologous to mammalian PIGZ) is essential for GPI biosynthesis, mammalian PIGZ disruption does not significantly affect GPI-anchored protein expression. This difference has been attributed to varying substrate recognition between mammalian and yeast GPI-EtNP transferase-III complexes .

How are GPI-anchored proteins detected in experimental settings?

Several complementary methods can be employed to detect GPI-anchored proteins:

For flow cytometry, cells should be harvested, washed with PBS, and stained with primary antibodies against GPI-anchored proteins at approximately 10 μg/ml. After washing, samples are incubated with fluorescently-conjugated secondary antibodies and analyzed using flow cytometry .

Why might fibroblasts be better than granulocytes for studying GPI biosynthesis defects?

Research has demonstrated significant cell type-specific differences in detecting GPI biosynthesis defects. Analysis of cells from patients with pathogenic variants in PIGG revealed:

• Fibroblasts showed markedly decreased levels of GPI anchors and specific GPI-linked markers (CD59, CD73, CD90) .

• Granulocytes from the same patients showed no altered GPI-anchored marker expression .

This differential sensitivity suggests that fibroblasts may be more suitable for screening GPI-anchor deficiencies. The mechanisms behind this cell type-specific response remain under investigation but may involve differences in compensatory pathways or the relative importance of specific GPI modifications in different cell types .

How do GPI-anchored single-chain antibodies contribute to HIV resistance strategies?

GPI-anchored single-chain antibodies represent a promising approach for generating HIV-resistant cells. Recent research has characterized a panel of HIV-1-neutralizing antibodies as GPI-anchored inhibitors:

• Fusion genes encoding single-chain variable fragments (scFv) of antibodies including 3BNC117, N6, PGT126, PGT128, 10E8, and 35O22 were constructed using self-inactivating lentiviral vectors .

• These constructs efficiently express in lipid raft sites of target cell membranes without disrupting HIV-1 receptor expression (CD4, CCR5, CXCR4) .

• Cells modified with GPI-10E8 demonstrated the most potent and broad anti-HIV activity, conferring resistance to:

  • Cell-free HIV-1 infection

  • Cell-associated HIV-1 transmission

  • Viral Env-mediated cell-cell fusion

Additionally, bifunctional constructs combining 10E8 with fusion inhibitor peptides rendered cells completely resistant to HIV-1, HIV-2, and simian immunodeficiency virus (SIV). In human CD4+ T cells, these modifications blocked both CCR5- and CXCR4-tropic HIV-1 isolates efficiently .

What is the relationship between GPI biosynthesis pathway dysfunction and autoimmunity?

PGAP3 knockout mice studies have revealed a significant link between GPI biosynthesis and autoimmunity:

• PGAP3 is responsible for fatty acid remodeling of GPI-APs, replacing an unsaturated fatty acid with a saturated one at the sn-2 position of phosphatidylinositol .

• Aged PGAP3-knockout mice developed autoimmune-like symptoms including:

  • Increased anti-DNA antibodies

  • Spontaneous germinal center formation

  • Enlarged renal glomeruli with immune complex deposition and matrix expansion

The mechanism appears to involve impaired engulfment of apoptotic cells by resident peritoneal macrophages in PGAP3-/- mice. Interestingly, conditional targeting of PGAP3 in either B or T cells alone did not reproduce these autoimmune symptoms, suggesting that GPI fatty acid remodeling affects multiple cell types in the immune system .

Additionally, PGAP3-/- mice exhibited Th2 polarization, indicating that GPI fatty acid remodeling plays a role in regulating Th1/Th2 balance, potentially through lipid raft organization effects on immune signaling .

How does the GPI biosynthesis pathway contribute to T cell exhaustion?

Recent research has identified a mechanistic link between the GPI-anchored biosynthetic pathway and T cell exhaustion, though the complete molecular mechanisms remain under investigation .

Analysis of differential gene expression between patient groups with varying GPI-score (a measure of GPI biosynthesis pathway activity) revealed:

• Patients with high GPI-score showed decreased adaptive immune function, with reductions in:

  • CD8+ T cells

  • CD4+ memory activated T cells

  • T follicular helper cells

  • Regulatory T cells (Tregs)

  • Gamma delta T cells

• This was accompanied by an increase in M2 macrophages (tumor-promoting) and monocytes .

• Higher GPI-anchored biosynthesis correlated with:

  • Diminished immune status and response

  • Decreased stromal cell infiltration in tumor tissues

  • Elevated levels of tumor purity

These findings suggest that modulation of GPI biosynthesis could potentially influence T cell function and exhaustion, with implications for immunotherapy approaches.

How can knockout cell libraries be constructed to study GPI biosynthesis genes?

A comprehensive approach to studying GPI biosynthesis involves creating knockout cell libraries using CRISPR-Cas9 technology:

• Design of knockout constructs:

  • Select at least two target sites on one exon of each gene

  • Design gRNAs to allow knockout confirmation by eliminating sequences on targeted exons

• Validation process:

  • Transfect pX330-EGFP plasmids containing gRNA sequences into HEK293 cells

  • Sort cells with high EGFP fluorescence signal after 3 days

  • Culture collected cells for over one week

  • Dilute and transfer to 96-well plates to obtain monoclonal knockout cells

  • Analyze gene knockout by Sanger sequencing

  • Select clonal cells without wild-type alleles

• Phenotypic characterization:

  • Analyze GPI-AP expression through flow cytometry

  • Assess sensitivity to PI-PLC

  • Determine structural signatures of GPIs recognized by aerolysin

  • Compare effects of gene knockouts between mammalian and yeast cells to identify conserved and divergent functions

This approach has successfully been used to create a library of 32 knockout cell lines covering genes involved in GPI biosynthesis, enabling systematic functional studies .

What are the optimal methods for analyzing GPI-anchored protein expression by flow cytometry?

For accurate assessment of GPI-anchored protein expression, follow this optimized protocol:

• Sample preparation:

  • Harvest approximately 10^6 cells per well

  • Wash with 500 μl PBS

• PI-PLC treatment (if confirming GPI anchoring):

  • Mix samples with reaction buffer (5 U/ml PI-PLC, 0.5% BSA, 5 mM EDTA, and 10 mM HEPES in DMEM without FCS)

  • Incubate at 37°C for 1.5 hours

  • Wash with PBS

• Antibody staining:

  • Stain cells with primary antibodies (10 μg/ml) against GPI-APs (anti-CD55, anti-CD59, anti-CD230, etc.) in FACS buffer (PBS with 1% BSA and 0.1% NaN3)

  • Incubate for 25 minutes on ice

  • Wash twice with FACS buffer

  • Stain with secondary antibody (10 μg/ml) in FACS buffer for 25 minutes on ice

  • Wash twice with FACS buffer

• Analysis:

  • Analyze using flow cytometer (e.g., Accuri C6)

  • Use appropriate software (Accuri C6, FlowJo) for data analysis

  • Compare mean fluorescence intensity (MFI) between samples

  • Apply non-parametric statistical tests for non-normally distributed data

This protocol has been effectively used to characterize GPI-AP expression in various knockout cell lines and can detect subtle differences in expression levels .

What strategies can be employed to study the functional significance of GPI13 in pathogen resistance?

To investigate GPI13's role in pathogen resistance, consider these approaches:

• Pathogen infection models:

  • Use GPI13/PIGO knockout or knockdown cell lines

  • Challenge with relevant pathogens (e.g., T. brucei, which depends on GPI biosynthesis)

  • Measure infection rates, pathogen replication, and host cell survival

• Drug target validation:

  • The GPI pathway has been validated as a drug target for treating African trypanosomiasis

  • GPI biosynthesis is essential to bloodstream form T. brucei parasites

  • Testing compounds that inhibit GPI13/PIGO specifically can help determine its importance in pathogen survival

• Host defense applications:

  • Engineer cells with GPI-anchored antimicrobial proteins

  • Similar to HIV-resistant cells created with GPI-anchored antibodies

  • Assess if GPI-anchored defense proteins can confer resistance to specific pathogens

• Comparative studies across species:

  • Compare the effects of GPI13/PIGO disruption between mammalian cells and pathogen cells

  • Identify differences in GPI biosynthesis that could be exploited for selective targeting

  • The GPI pathways of protozoan pathogens are likely good targets for novel therapeutics

How should researchers interpret cell type-specific differences in GPI biosynthesis defects?

When confronted with divergent results between cell types, consider these interpretation frameworks:

• Differential sensitivity to detection:

  • Fibroblasts consistently show more pronounced reductions in GPI-anchored proteins compared to blood cells like granulocytes

  • This may reflect methodological limitations rather than actual biological differences

• Varying compensatory mechanisms:

  • Different cell lineages may possess alternative pathways that can partially compensate for GPI biosynthesis defects

  • The absence of clinical manifestations in certain tissues despite GPI deficiency supports this hypothesis

• Analysis approach:

  • When studying a new GPI biosynthesis gene, examine multiple cell types

  • Use complementary detection methods (flow cytometry, Western blotting, functional assays)

  • Compare multiple GPI-anchored markers, as some (like CD55) may be less affected than others (CD59, CD73, CD90)

• Regulatory vs. catalytic subunits:

  • Knockout of regulatory subunits like PIGQ and PIGY may retain partial GPI-GnT activity

  • This explains why KO of these genes maintains weak expression of GPI-APs while KO of catalytic subunits completely eliminates expression

What are the common pitfalls in studying GPI13 antibody specificity and how can they be avoided?

Several challenges can compromise GPI13 antibody studies:

• Cross-reactivity issues:

  • GPI biosynthesis proteins share structural similarities

  • Validate antibody specificity using knockout cell lines as negative controls

  • Include positive controls with known GPI13/PIGO expression

• Detection limitations:

  • Direct detection of GPI13/PIGO can be difficult due to relatively low expression levels

  • Instead, measure downstream effects on GPI-anchored protein expression

  • Use multiple GPI-anchored proteins as readouts (CD55, CD59, CD73, CD90)

• Functional redundancy:

  • Some GPI biosynthesis enzymes have partially overlapping functions

  • Use complementation analysis with homologous genes from different species to distinguish specific functions

  • The GPI-KO cell library can be utilized for complementation analysis of homologous genes in different species

• Validation approaches:

  • Confirm antibody specificity through immunoprecipitation followed by mass spectrometry

  • Use transcriptome analysis to correlate protein detection with mRNA expression

  • Compare parental cells with AmpliSeq data where gene expression is verified

How can researchers distinguish between primary effects of GPI13 disruption and secondary cellular adaptations?

Differentiating immediate consequences from adaptive responses requires careful experimental design:

• Temporal analysis:

  • Implement inducible knockout or knockdown systems (e.g., Tet-On/Off)

  • Track changes at multiple timepoints (hours, days, weeks) after GPI13 disruption

  • Early changes likely represent primary effects, while later changes may indicate adaptation

• Rescue experiments:

  • Reintroduce wild-type GPI13/PIGO after knockout

  • Effects that rapidly normalize are likely primary consequences

  • Persistent abnormalities despite rescue suggest secondary adaptations or irreversible changes

• Pathway intervention:

  • Target different steps in GPI biosynthesis

  • Compare phenotypes between GPI13/PIGO disruption and disruption of other pathway components

  • Shared phenotypes indicate primary pathway effects rather than protein-specific functions

• Multi-omics approach:

  • Combine transcriptomics, proteomics, and functional assays

  • Identify early changes in gene expression or protein localization

  • Map results to known signaling pathways to distinguish direct and indirect effects